OBOSTRENIE KhRONIChESKOY OBSTRUKTIVNOY BOLEZNI LEGKIKh. ROL' I MESTO ORAL'NYKh TsEFALOSPORINOV III POKOLENIYa

Chronic obstructive pulmonary disease (COPD) is one of the most common human diseases, and this allows talking about the global epidemic of the disease, the true scale and consequences of which are yet to be determined. Recurrent exacerbations of disease corresponding with the rate of decrease of lung function, decline in the quality of life, and mortality are the quintessence of COPD. In the complex treatment of patients with acute exacerbation of COPD, antimicrobial drugs which have testing by time, and maintaining high activity against pathogens and remaining the one of the therapeutic preferences of the modern physicians, occupy a special place. These include and cefixime - the first III generation oral cephalosporins. The antibiotic is characterized by the long half-life (3-4 hours) among of all oral cephalosporins, which allows to appoint it once a day. Cefixime is active against most bacterial pathogens of nonsevere COPD exacerbations - Haemophilus influenzae, Moraxella catarrhalis, susceptible strains of Streptococcus pneumoniae, Gramnegative enterobacteria. Many clinical studies have demonstrated the clinical efficacy of cefixime in excess of80-85 % and comparable to that of «respiratory» fluoroquinolones and amoxicillin/clavulanate.

chronic obstructive pulmonary disease (COPD), exacerbation of COPD, antibacterial therapy, oral cephalosporins, cefixime